 PLYMOUTH MEETING, Pa., Aug. 9, 2021 PRNewswire -- Harmony Biosciences Holdings, Inc. Harmony Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, today announced the acquisition of HBS-102 formerly CSTI-100, a potential first-in-class molecule with a novel mechanism of action, from ConSynance Therapeutics, Inc., a clinical stage biotechnology company focused on rare central nervous system diseases. 